[Prediction of effectiveness of antihypertensive treatment in patients with consideration of the role of polymorphisms of angiotensin receptors ATR1].

to elucidate the prognostic role of angiotensin receptor (ATR1) gene polymorphism relative to progression of the disease and effectiveness of antihypertensive therapy. We included in this study 132 consecutive patients (48 women [36.4%, mean age 51.6 years] and 84 men [63.6%, mean age 49.4 years) with diagnosis of arterial hypertension (AH), who underwent echocardiography not less than 10 months from the date of entry into the study. Mean duration of follow-up was about 5 years. In all patients we determined belonging to one of variants of polymorphic A1166C gene: AA, AC, or CC. This allowed us to divide them into 2 groups: carriers of allele A (group A) and allele C (group C). In both groups we observed significant regression of left ventricular myocardial mass (LVMM) in those patients who achieved target BP. No significant changes of LVMM were noted in patients with partially effective or ineffective antihypertensive treatment (AHT). Regression of LVMM was observed more frequently among patients taking angiotensin receptor blockers (ARBs) compared with those who used angiotensin converting enzyme inhibitors (ACEI). Thus it was established that irrespective of the structure of polymorphic ATR1 gene there existed a parallelism of antihypertensive and antiremodelling efficacy of treatment of AH. Besides that, the ATR1 gene polymorphism can be considered as an additional factor determining efficacy of AHT. In particular, carriers of C allele respond better to therapy with ARBs, and carriers of A allele--with ACEI. In this case, the carriers of allele C can be expected to decrease their LVMM more expressive than carriers of the allele A.